CN108690134B - 用于治疗乙肝感染及相关疾病的抗体 - Google Patents

用于治疗乙肝感染及相关疾病的抗体 Download PDF

Info

Publication number
CN108690134B
CN108690134B CN201810307136.5A CN201810307136A CN108690134B CN 108690134 B CN108690134 B CN 108690134B CN 201810307136 A CN201810307136 A CN 201810307136A CN 108690134 B CN108690134 B CN 108690134B
Authority
CN
China
Prior art keywords
seq
antibody
antigen
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810307136.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN108690134A (zh
Inventor
罗文新
王一文
康赐明
袁权
张天英
夏宁邵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yang Sheng Tang Co Ltd
Xiamen University
Original Assignee
Yang Sheng Tang Co Ltd
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yang Sheng Tang Co Ltd, Xiamen University filed Critical Yang Sheng Tang Co Ltd
Priority to CN202110762624.7A priority Critical patent/CN113480641B/zh
Publication of CN108690134A publication Critical patent/CN108690134A/zh
Application granted granted Critical
Publication of CN108690134B publication Critical patent/CN108690134B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201810307136.5A 2017-04-07 2018-04-08 用于治疗乙肝感染及相关疾病的抗体 Active CN108690134B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110762624.7A CN113480641B (zh) 2017-04-07 2018-04-08 用于治疗乙肝感染及相关疾病的抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710223992 2017-04-07
CN2017102239928 2017-04-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110762624.7A Division CN113480641B (zh) 2017-04-07 2018-04-08 用于治疗乙肝感染及相关疾病的抗体

Publications (2)

Publication Number Publication Date
CN108690134A CN108690134A (zh) 2018-10-23
CN108690134B true CN108690134B (zh) 2021-07-30

Family

ID=63712017

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810307136.5A Active CN108690134B (zh) 2017-04-07 2018-04-08 用于治疗乙肝感染及相关疾病的抗体
CN202110762624.7A Active CN113480641B (zh) 2017-04-07 2018-04-08 用于治疗乙肝感染及相关疾病的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110762624.7A Active CN113480641B (zh) 2017-04-07 2018-04-08 用于治疗乙肝感染及相关疾病的抗体

Country Status (4)

Country Link
KR (2) KR20200010217A (ko)
CN (2) CN108690134B (ko)
RU (1) RU2765878C2 (ko)
WO (1) WO2018184593A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020280539A1 (en) * 2019-05-23 2022-01-27 Xiamen University Novel anti-hepatitis B virus antibody and uses thereof
CN115236331A (zh) * 2020-11-11 2022-10-25 南京诺唯赞生物科技股份有限公司 一种检测SARS-CoV-2中和抗体的试剂盒及方法
CN113683684B (zh) * 2021-06-21 2023-07-18 深圳市新产业生物医学工程股份有限公司 抗乙肝病毒表面抗原抗体、抗体对、含有其的检测试剂及试剂盒
CN115677852B (zh) * 2021-07-29 2023-11-10 东莞市朋志生物科技有限公司 一种抗HBeAg抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608626D0 (en) * 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
JP4948783B2 (ja) * 2005-05-18 2012-06-06 シスメックス株式会社 抗ＨＢｓモノクローナル抗体
AP2010005354A0 (en) * 2008-01-23 2010-08-31 Acharya Subrat K A humanized high affinity recombinant antibody against hepatitis B surface antigen
DE102009028940A1 (de) * 2009-08-27 2011-03-03 Robert Bosch Gmbh Antriebsvorrichtung für eine Scheibenwischereinrichtung
KR101072895B1 (ko) * 2009-12-24 2011-10-17 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원에 특이적으로 결합하는 인간 항체
CA2805564A1 (en) * 2010-08-05 2012-02-09 Stefan Jenewein Anti-mhc antibody anti-viral cytokine fusion protein
CN101943700A (zh) * 2010-09-10 2011-01-12 珠海丽珠试剂股份有限公司 乙型肝炎病毒表面抗原呈阳性的确认方法和试剂盒
CN102786592A (zh) * 2011-05-17 2012-11-21 傅阳心 Hbv特异性抗体
KR101281098B1 (ko) * 2011-06-30 2013-07-02 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도
CN103483421B (zh) * 2012-06-11 2019-10-22 厦门大学 用于治疗hbv感染及相关疾病的多肽及抗体
CN103588874B (zh) * 2013-11-11 2015-06-17 中国疾病预防控制中心病毒病预防控制所 一种人源抗乙肝病毒表面抗原基因工程抗体、其制备方法及应用
CN105001325A (zh) * 2015-07-31 2015-10-28 北京泰诺迪生物科技有限公司 一种全人源抗乙肝病毒中和抗体及其制备方法与应用
CN105061590B (zh) * 2015-08-03 2019-06-04 中国人民解放军第二军医大学 针对乙肝表面蛋白的双特异性抗体及其用途

Also Published As

Publication number Publication date
CN113480641A (zh) 2021-10-08
RU2019135404A (ru) 2021-05-07
KR102561555B1 (ko) 2023-07-31
RU2019135404A3 (ko) 2021-05-07
CN108690134A (zh) 2018-10-23
KR20220126788A (ko) 2022-09-16
WO2018184593A1 (zh) 2018-10-11
KR20200010217A (ko) 2020-01-30
RU2765878C2 (ru) 2022-02-04
CN113480641B (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
CN108690134B (zh) 用于治疗乙肝感染及相关疾病的抗体
CN113929771A (zh) 多瘤病毒中和抗体
CN106565840B (zh) 抗乙肝表面抗原的抗体及其用途
JP2012513457A (ja) Ｈｃｖ感染の治療的処置および予防のための医薬としての抗ｈｃｖモノクローナル抗体
RU2803082C2 (ru) Антитела против вируса гепатита в и их применение
EP3981786A1 (en) Novel anti-hepatitis b virus antibody and uses thereof
CN113549146B (zh) 针对柯萨奇病毒b1型的单克隆抗体及其用途
RU2814471C2 (ru) Новые антитела против вируса гепатита b и их применение
CN114174331B (zh) 结合人类偏肺病毒融合蛋白的抗体及其用途
US20220340644A1 (en) Influenza neutralizing antibodies and their uses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant